Integra LifeSciences Holdings Corp. (IART)
11.91
-0.42
(-3.37%)
USD |
NASDAQ |
Oct 23, 16:00
11.90
-0.01
(-0.08%)
After-Hours: 20:00
Integra LifeSciences Holdings Enterprise Value : 2.617B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 2.617B |
| October 22, 2026 | 2.649B |
| October 21, 2026 | 2.612B |
| October 20, 2026 | 2.727B |
| October 19, 2026 | 2.737B |
| October 16, 2026 | 2.718B |
| October 15, 2026 | 2.743B |
| October 14, 2026 | 2.715B |
| October 13, 2026 | 2.768B |
| October 12, 2026 | 2.778B |
| October 09, 2026 | 2.736B |
| October 08, 2026 | 2.734B |
| October 07, 2026 | 2.702B |
| October 06, 2026 | 2.727B |
| October 05, 2026 | 2.724B |
| October 02, 2026 | 2.677B |
| October 01, 2026 | 2.942B |
| September 30, 2026 | 2.957B |
| September 29, 2026 | 3.069B |
| September 28, 2026 | 3.040B |
| September 25, 2026 | 3.029B |
| September 24, 2026 | 3.010B |
| September 23, 2026 | 2.983B |
| September 22, 2026 | 3.021B |
| September 21, 2026 | 2.987B |
| Date | Value |
|---|---|
| September 18, 2026 | 2.959B |
| September 17, 2026 | 2.949B |
| September 16, 2026 | 3.024B |
| September 15, 2026 | 2.995B |
| September 14, 2026 | 2.997B |
| September 11, 2026 | 2.980B |
| September 10, 2026 | 2.983B |
| September 09, 2026 | 3.039B |
| September 08, 2026 | 3.039B |
| September 04, 2026 | 3.075B |
| September 03, 2026 | 3.053B |
| September 02, 2026 | 3.082B |
| September 01, 2026 | 3.067B |
| August 31, 2026 | 3.091B |
| August 28, 2026 | 3.088B |
| August 27, 2026 | 3.085B |
| August 26, 2026 | 3.088B |
| August 25, 2026 | 3.081B |
| August 24, 2026 | 3.073B |
| August 21, 2026 | 3.077B |
| August 20, 2026 | 3.065B |
| August 19, 2026 | 3.116B |
| August 18, 2026 | 3.140B |
| August 17, 2026 | 3.148B |
| August 14, 2026 | 3.201B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Penumbra, Inc. | 12.33B |
| Abbott Laboratories | 207.10B |
| Boston Scientific Corp. | 78.32B |
| Globus Medical, Inc. | 10.45B |
| Sight Sciences, Inc. | 454.12M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 14.85M |
| Revenue (Quarterly) | 411.18M |
| Total Expenses (Quarterly) | 396.33M |
| EPS Diluted (Quarterly) | 0.189 |
| Gross Profit Margin (Quarterly) | 54.63% |
| Profit Margin (Quarterly) | 3.61% |
| Earnings Yield | 1.38% |
| Operating Earnings Yield | 20.77% |
| Normalized Earnings Yield | 9.400 |